LOINC Laboratory Committee Meeting
Date: 2026-09-17
Time: 9:00 -10:00 a.m. EDT / 1:00 - 2:00 p.m. UTC
Chair: Pam Banning

ATTENDEES

Committee Members:

1. **Pam Banning (Chair)**
    a. **Chris Gordon**
2. **Andrea Pitkus**
3. Jenna Rychert
    a. Ben Brisbay
    b. Spencer Siady
4. Xavier Gansel
    a. Mike Dante
5. Miereia Rodriguez Naque
    a. Vicky Berez
    b. **Gloria Gonzalez**
    c. **Nuria Planas Acero**
6. **Anil Patel**
    a. **Linda Monico**
    b. Tarek Kadoura
7. Simone Arvisais-Anhalt
    a. Alex Mays
8. Daniel Vreeman
9. Stanley Huff
    a. Nathan Davis
    b. Doug Mitchell
10. Jessie Wright
11. Leanna Harmon
    a. Michelle Kincer
    b. Kimberly Rich
    c. **Laura Lemonds**
12. **Leticia Linhares**
13. Maureen Slackway
14. Joseph Yao
    a. Candace Byrge
    b. **Carla Ihrke**
15. Michael Martin
16. Tiffany Paulsen
17. **John Snyder**
    a. Liz Amos
18. **Feikje Hielkema**
    a. Inge Soons
19. Alex Milinovich
20. Kimberly Scott
    a. **Kimberly Brown**
21. Jeremy Sonnenmoser
22. **Tina Johnson**
    a. Cindy Martin
23. Andrea Wu
24. **Riki Merrick**

Regenstrief Staff:
April Lackey, Geoffrey Ratemo, Steven Wagers

Guests:
Salve Achacoso, Maria Fodor

Committee Members = 24 | # Attending = 12 | Quorum = Yes

Meeting Summary

SHIELD update
Discussion:

- The upcoming face-to-face SHIELD meeting will be held at North Bethesda with both in-person and virtual attendance options.
- Priority discussion items include common lab results for national data sharing, LIS/LIMS interoperability needs, order/result mapping functionality, and limitations in EHR support for certain code systems.
- The group also plans to discuss LOI and LRI version 2.51 alignment and vendor-provided LIVD link maps to improve mapping availability.
- A separate steering committee discussion with ONC is planned to address laboratory interoperability challenges.

Decisions: None
Next steps: None

Drug/Tox Part II 2.83 Update
Discussion:

- The 2.83 release introduced updates to Drug/Tox codes, with a phased rollout rather than a single full conversion.
- Some codes still have screening and confirmation concepts where methodless versions were not yet built.
- A few inconsistencies were identified in the updated codes, including at least one specific code flagged for review.
- The group expects remaining work to continue into the February release, with additional panel planning to follow.
- It was noted that a code using an impression scale for a drug tox concept appears unusual and may warrant future review.
- The question of whether discouraged codes will be deprecated was raised, but deprecation is not currently planned.

Decisions: None
Next steps: None

Molecular genetics
Discussion:

- Over 1,000 new or renamed micronucleotide detection concepts were reviewed, including terms using curly-brace notation for specimen and molecular genetics.
- Search behavior does not handle curly braces intuitively, making it harder for users to find the relevant terms.
- It was noted that escaping the braces works technically, but that approach is not usable for average mappers.
- The search issue was identified as a candidate for improvement in LOINC tooling.

Decisions: None
Next steps: None

Entitic volume vs entitic mean volume

Discussion:

- A UK pathology group raised a question about whether entitic volume and entitic mean volume should be merged.
- The discussion concluded that microscopic cellular measurements and macroscopic entity measurements should remain distinct.
- Mean volume concepts remain appropriate for cellular indices, while entitic volume is more appropriate for larger measurable entities such as stones.
- It was noted that some cleanup may still be needed where mean volume appears in component naming.

Decisions: None
Next steps: None

Forum questions: Complement C1-esterase

- Canadian examples showed inconsistent reporting for C1 esterase functional assays, including percentage, mg/L, and other unit expressions.
- The group reviewed historical and current concepts, including a legacy code and a newer concept related to functional activity.
- There is concern that some laboratories may be mapping antigen/protein concentration results to functional concepts, creating potential mismatch.
- Guidance may be needed to clarify how legacy terms should be used and whether current assay methodologies should map to relative functional activity concepts.
- It was suggested that additional reference lab and vendor research would help determine mapping consistency.

Follow-up Tasks

1. Drug/Tox steps:
    a. Break up and deliver the remaining ~1,240 component/specimen combinations into a build file to support method-specific LOINC creation.
    b. Coordinate with the software team to build the comprehensive list for Drug Tox (screen vs confirm components)
    c. Ensure verification that a method/analyte combination actually exists before creating new LOINC entries for those combinations.
        i. Leads: Pam Banning, Eza Hafeza, Steven Wagers
        ii. Date identified: 2026-03-19
        iii. Due date: TBD
        iv. Status: Open

New Follow-up Tasks: None

REFERENCE MATERIALS

- LOINC Laboratory Committee_Meeting Agenda_2026-09-17_Final
- LaboratoryCommittee_MeetingSlides_2026-09-17_final.pptx
- LOINC Laboratory Committee_Meeting Summary_2026-06-18_Final.docx
- Entitic volume vs Entitic mean volume.docx
- LabMeeting_Chat_2026-09-17

Next Meeting

- 2026-10-15, 9:00 -10:00 a.m. EDT / 1:00 - 2:00 p.m. UTC
- Tentative agenda topics
    - LOINC Conference

Parked Topics

- Codes that use Property “impression” with a scale of “ordinal” like https://loinc.org/114412-0. Need to assess how many examples there are.